Type 2 diabetes, psoriasis and thiazolidinediones
Type 2 diabetes, psoriasis and thiazolidinediones
Thiazolidinediones, synthetic ligands for the peroxisome proliferator-activated receptor-? (PPAR-?) receptor, are insulin-sensitizing drugs licensed for use in selected patients with type 2 diabetes mellitus. The potential therapeutic applications of the thiazolidinediones extend to other clinical specialities such as dermatology. Rosiglitazone and pioglitazone are being evaluated for the treatment of psoriasis. Type 2 diabetes and psoriasis may coexist prompting speculation that dual benefits might accrue for patients with both conditions. A recent open pilot study suggests that oral pioglitazone may be beneficial for moderate chronic plaque psoriasis. However, changes in antidiabetic medication must be made in the knowledge of the cautions and contraindications to oral agents as well as the impact on metabolic control. Further studies are required before the use of thiazolidinediones for psoriasis can be advocated.
362-363
Krentz, A.J.
9f3c00da-2737-4e5f-9403-e803af2744f6
Friedmann, P.S.
d50bac23-f3ec-4493-8fa0-fa126cbeba88
2006
Krentz, A.J.
9f3c00da-2737-4e5f-9403-e803af2744f6
Friedmann, P.S.
d50bac23-f3ec-4493-8fa0-fa126cbeba88
Krentz, A.J. and Friedmann, P.S.
(2006)
Type 2 diabetes, psoriasis and thiazolidinediones.
International Journal of Clinical Practice, 60 (3), .
(doi:10.1111/j.1368-5031.2005.00765.x).
Abstract
Thiazolidinediones, synthetic ligands for the peroxisome proliferator-activated receptor-? (PPAR-?) receptor, are insulin-sensitizing drugs licensed for use in selected patients with type 2 diabetes mellitus. The potential therapeutic applications of the thiazolidinediones extend to other clinical specialities such as dermatology. Rosiglitazone and pioglitazone are being evaluated for the treatment of psoriasis. Type 2 diabetes and psoriasis may coexist prompting speculation that dual benefits might accrue for patients with both conditions. A recent open pilot study suggests that oral pioglitazone may be beneficial for moderate chronic plaque psoriasis. However, changes in antidiabetic medication must be made in the knowledge of the cautions and contraindications to oral agents as well as the impact on metabolic control. Further studies are required before the use of thiazolidinediones for psoriasis can be advocated.
This record has no associated files available for download.
More information
Published date: 2006
Identifiers
Local EPrints ID: 27210
URI: http://eprints.soton.ac.uk/id/eprint/27210
PURE UUID: 463b4bd9-f5a1-40b5-bc16-ed91133fb05a
Catalogue record
Date deposited: 25 Apr 2006
Last modified: 15 Mar 2024 07:16
Export record
Altmetrics
Contributors
Author:
A.J. Krentz
Author:
P.S. Friedmann
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics